Yan Hiu Athena Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan Hiu Athena Lee has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Danish Iltaf Satti
Heart Failure and Structural Heart Disease Unit, Cardiovascular Analytics Group, Hong Kong, China—United Kingdom collaboration
2 shared publications - Gary Tse
School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China
2 shared publications - Jeffrey Shi Kai Chan
Cardio-Oncology Research Unit, Cardiovascular Analytics Group, School of Nursing and Health Sciences, Hong Kong Metropolitan University, Hong Kong, China
2 shared publications - Jeremy Man Ho Hui
Cardiovascular Analytics Group
2 shared publications Alex Liu
CUHK, Hong Kong, China
1 shared publication- Ana Ciobanu
Department of Cardiology, “Prof. Dr. Agrippa Ionescu” Emergency Clinical Hospital, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
1 shared publication
Latest Publications
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA5113
Comparison of pneumonia and sepsis risks between enzalutamide and abiraterone in patients with prostate cancer
Importance: Enzalutamide and abiraterone may differ in their immunomodulatory effects, and the prednisone co-administered with abiraterone can be immunosuppressive. Objective: This study aimed to compare the risk of different types of infection in prostate cancer (PCa) patients receiving enzalutamide or abiraterone in combination with ADT. Design: Retrospective cohort study. Setting: Population-based study. Participants: Patients with PCa receiving either enzalutamide or abiraterone in addition to ADT in Hong Kong between December 1999 to March 2021 were identified. They were followed up until September 2021 or censoring event including death and crossover. Exposures: Patients were divided according to enzalutamide or abiraterone use. Main outcomes and measures: Pneumonia and sepsis were analyzed as both time-to-event outcomes (multivariable Fine-Gray regression, with mortality considered a competing event) and recurrent-event outcomes (multivariable negative binomial regression). Results: 1582 patients were analyzed (abiraterone group: 923; enzalutamide group: 659) with a median follow-up of 10.6 months (interquartile range: 5.3-19.9 months). Compared to abiraterone users, enzalutamide users had lower cumulative incidences of pneumonia (aSHR 0.76 [0.59-0.99]) and sepsis (adjusted subhazard ratio [aSHR] 0.70 [0.53-0.93], p=0.014). The associations between enzalutamide use and lower risk of pneumonia may be stronger in patients ≤70 years old. Conclusions: Enzalutamide users have a significantly lower risk of pneumonia and sepsis.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA5113
Comparison of pneumonia and sepsis risks between enzalutamide and abiraterone in patients with prostate cancer
Importance: Enzalutamide and abiraterone may differ in their immunomodulatory effects, and the prednisone co-administered with abiraterone can be immunosuppressive. Objective: This study aimed to compare the risk of different types of infection in prostate cancer (PCa) patients receiving enzalutamide or abiraterone in combination with ADT. Design: Retrospective cohort study. Setting: Population-based study. Participants: Patients with PCa receiving either enzalutamide or abiraterone in addition to ADT in Hong Kong between December 1999 to March 2021 were identified. They were followed up until September 2021 or censoring event including death and crossover. Exposures: Patients were divided according to enzalutamide or abiraterone use. Main outcomes and measures: Pneumonia and sepsis were analyzed as both time-to-event outcomes (multivariable Fine-Gray regression, with mortality considered a competing event) and recurrent-event outcomes (multivariable negative binomial regression). Results: 1582 patients were analyzed (abiraterone group: 923; enzalutamide group: 659) with a median follow-up of 10.6 months (interquartile range: 5.3-19.9 months). Compared to abiraterone users, enzalutamide users had lower cumulative incidences of pneumonia (aSHR 0.76 [0.59-0.99]) and sepsis (adjusted subhazard ratio [aSHR] 0.70 [0.53-0.93], p=0.014). The associations between enzalutamide use and lower risk of pneumonia may be stronger in patients ≤70 years old. Conclusions: Enzalutamide users have a significantly lower risk of pneumonia and sepsis.
- Open Access
- 28 February 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (4) , 1843-1849
The modified Rajan’s heart failure risk score predicts all-cause mortality in patients hospitalized for heart failure with reduced ejection fraction: a retrospective cohort study
Background: The dimensionless Rajan’s heart failure (R-hf) risk score was proposed to predict all-cause mortality in patients hospitalized with chronic heart failure (HF) and reduced ejection fraction (EF) (HFrEF). Purpose: To examine the association between the modified R-hf risk score and all-cause mortality in patients with HFrEF. Methods: Retrospective cohort study included adults hospitalized with HFrEF, as defined by clinical symptoms of HF with biplane EF less than 40% on transthoracic echocardiography, at a tertiary centre in Dalian, China, between 1 November 2015, and 31 October 2019. All patients were followed up until 31 October 2020. A modified R-hf risk score was calculated by substituting brain natriuretic peptide (BNP) for N-terminal prohormone of BNP (NT-proBNP) using EF× estimated glomerular filtration rate (eGFR)× haemoglobin (Hb))/BNP. The patients were stratified into tertiles according to the R-hf risk score. The measured outcome was all-cause mortality. The score performance was assessed using C-statistics. Results: A total of 840 patients were analyzed (70.2% males; mean age, 64±14 years; median (interquartile range) follow-up 37.0 (27.8) months). A lower modified R-hf risk score predicted a higher risk of all-cause mortality, independent of sex and age [1st tertile vs. 3rd tertile: adjusted hazard ratio (aHR), 3.46; 95% CI: 2.11–5.67; PPP=0.004)]. The performance of the model, as reported by C-statistic was 0.67 (95% CI: 0.62–0.72). Conclusion: The modified R-hf risk score predicted all-cause mortality in patients hospitalized with HFrEF. Further validation of the modified R-hf risk score in other cohorts of patients with HFrEF is needed before clinical application.
- 28 February 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (4) , 1843-1849
Open AccessThe modified Rajan’s heart failure risk score predicts all-cause mortality in patients hospitalized for heart failure with reduced ejection fraction: a retrospective cohort study
Background: The dimensionless Rajan’s heart failure (R-hf) risk score was proposed to predict all-cause mortality in patients hospitalized with chronic heart failure (HF) and reduced ejection fraction (EF) (HFrEF). Purpose: To examine the association between the modified R-hf risk score and all-cause mortality in patients with HFrEF. Methods: Retrospective cohort study included adults hospitalized with HFrEF, as defined by clinical symptoms of HF with biplane EF less than 40% on transthoracic echocardiography, at a tertiary centre in Dalian, China, between 1 November 2015, and 31 October 2019. All patients were followed up until 31 October 2020. A modified R-hf risk score was calculated by substituting brain natriuretic peptide (BNP) for N-terminal prohormone of BNP (NT-proBNP) using EF× estimated glomerular filtration rate (eGFR)× haemoglobin (Hb))/BNP. The patients were stratified into tertiles according to the R-hf risk score. The measured outcome was all-cause mortality. The score performance was assessed using C-statistics. Results: A total of 840 patients were analyzed (70.2% males; mean age, 64±14 years; median (interquartile range) follow-up 37.0 (27.8) months). A lower modified R-hf risk score predicted a higher risk of all-cause mortality, independent of sex and age [1st tertile vs. 3rd tertile: adjusted hazard ratio (aHR), 3.46; 95% CI: 2.11–5.67; PPP=0.004)]. The performance of the model, as reported by C-statistic was 0.67 (95% CI: 0.62–0.72). Conclusion: The modified R-hf risk score predicted all-cause mortality in patients hospitalized with HFrEF. Further validation of the modified R-hf risk score in other cohorts of patients with HFrEF is needed before clinical application.
- Open Access
- 26 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (21) , 12963
Arrhythmias and Conduction Disturbances in Patients with Systemic Sclerosis—A Systematic Literature Review
Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and internal organ fibrosis and microvascular impairment, which can affect major organs, including the heart. Arrhythmias are responsible for approximately 6% of deaths in patients with SSc, and mainly occur due to myocardial fibrosis, which causes electrical inhomogeneity. The aim of this study was to determine the frequency of arrhythmias and conduction disturbances in SSc cohorts, and to identify the characteristics and risk factors associated with the occurrence of dysrhythmias in patients with SSc. A systematic literature review using PubMed, Embase, Web of Science and Scopus databases was performed. Full-text articles in English with arrhythmias as the main topic published until 21 April 2022 were included. Most prevalent arrhythmias were premature supraventricular and ventricular contractions, while the most frequent conduction disturbance was represented by right bundle branch block (RBBB). Elevated concentrations of N-terminal prohormones of brain natriuretic peptides (NT-pro BNP) were associated with numerous types of atrial and ventricular arrhythmias, and with the occurrence of RBBB. A lower value of the turbulence slope (TS) emerged as an independent predictor for ventricular arrhythmias. In conclusion, dysrhythmias are frequent in SSc cohorts. Paraclinical and laboratory parameters are useful instruments that could lead to early diagnosis in the course of the disease.
- 26 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (21) , 12963
Open AccessArrhythmias and Conduction Disturbances in Patients with Systemic Sclerosis—A Systematic Literature Review
Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and internal organ fibrosis and microvascular impairment, which can affect major organs, including the heart. Arrhythmias are responsible for approximately 6% of deaths in patients with SSc, and mainly occur due to myocardial fibrosis, which causes electrical inhomogeneity. The aim of this study was to determine the frequency of arrhythmias and conduction disturbances in SSc cohorts, and to identify the characteristics and risk factors associated with the occurrence of dysrhythmias in patients with SSc. A systematic literature review using PubMed, Embase, Web of Science and Scopus databases was performed. Full-text articles in English with arrhythmias as the main topic published until 21 April 2022 were included. Most prevalent arrhythmias were premature supraventricular and ventricular contractions, while the most frequent conduction disturbance was represented by right bundle branch block (RBBB). Elevated concentrations of N-terminal prohormones of brain natriuretic peptides (NT-pro BNP) were associated with numerous types of atrial and ventricular arrhythmias, and with the occurrence of RBBB. A lower value of the turbulence slope (TS) emerged as an independent predictor for ventricular arrhythmias. In conclusion, dysrhythmias are frequent in SSc cohorts. Paraclinical and laboratory parameters are useful instruments that could lead to early diagnosis in the course of the disease.